Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply

Linked Content This article is linked to Goncalves et al and Pouillon et al papers. To view these articles visit https://doi.org/10.1111/apt.14808 and https://doi.org/10.1111/apt.14847.

Saved in:
Bibliographic Details
Published inAlimentary pharmacology & therapeutics Vol. 48; no. 5; pp. 575 - 576
Main Authors Goncalves, J., Magro, F., Danese, S., Lakatos, P. L., Ben‐Horin, S.
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.09.2018
Subjects
Epitopes
Infliximab
Monoclonal antibodies
Tumor necrosis factor-α
Online AccessGet full text

Cover

More Information
Summary:Linked Content This article is linked to Goncalves et al and Pouillon et al papers. To view these articles visit https://doi.org/10.1111/apt.14808 and https://doi.org/10.1111/apt.14847.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.14860